Research programme: surfactant protein-A derived asthma therapeutics - RaeSedo
Latest Information Update: 28 Jun 2024
At a glance
- Originator RaeSedo
- Class Anti-inflammatories; Antiasthmatics; Peptidomimetics
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 16 Nov 2022 RaeSedo plans human clinical trial for Asthma
- 07 Sep 2021 RaeSedo has patent protection for surfactant protein-A derived asthma therapeutics in USA (RaeSedo website, November 2022)